Volume: 7 Issue: 1
Year: 2019, Page: 75-78,
Introduction: Drugs used in pharmacotherapy are known to cause adverse reactions along with its useful therapeutic effects. Pharmacotherapy is the common modality of treatment for seizures and epilepsies. Despite the availability of many pharmacotherapeutic agents for the management of epilepsies, even today the broad spectrum anti-epileptic drugs like phenytoin and carbamazepine are frequently prescribed owing to their effectiveness. Here with this retrospective study an attempt has been made to understand the different adverse reactions developed especially serious reactions with the phenytoin and carbamazepine.
Materials and Methods :It’s a retrospective study; data is collected from case sheets and adverse drug reaction reporting forms.
Results:In this retrospective study we noted serious reactions like Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Out of 100 reactions studied 72% are with phenytoin and 28% are with carbamazepine.
Conclusion:The study is intended to project the seriousness of adverse reactions with commonly prescribed anti-epileptic drugs. There is a need for further studies especially prospective safety and efficay studies.
Keywords: Adverse reactions, Phenytoin, Carbamazepine, Serious reactions, SJS, TEN
1. Brunton L, Chabner B, Knollman B. Goodman & Gilman's. The Pharmacological Basis of Therapeutics, 12th ed. New York: Tata McGraw-Hills companies; pg 583 – 606.
2. Alldredge BK et.al. Koda-Kimble & Young’s Applied Therapeutics The clinical use of Drugs. 10th ed. Philadelphia: Lippincott Williams & Wilkins; Pg. 1387- 1418.
3. Griffin EA Jr., Lowenstein DH, Golan\14 Pharmacology of Abnormal Electrical Neurotransmission in the Central Nervous System.html; Golan DE, Jr Tashjian AH, Armstrong EJ, Armstrong AW. Principles of Pharmacology The Pathophysiologic Basis of Drug Therapy. 2nd ed. Philadelphia: Lippincott Williams and Wilkins.
4. Shuen-Iu Hung et.al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenetics and Genomics 2006; 16:297–306. Lippincott Williams & Wilkins.
5. P. Tennis, R.S. Stern. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: A record linkage study. NEUROLOGY 49 August 1997; 1997 by the American Academy of Neurology.
6. A.T.Berg et al. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005– 2009. Special report. Epilepsia 2010; 51(4):676–685. Wiley Periodicals, Inc.
7. R.S. Fisher et al. Epileptic seizures and epilepsy: Definitions proposed by the international league against epilepsy (ILAE) and the international bureau for epilepsy (IBE). Special article. Epilepsia 2005; 46(4):470–472. Blackwell publishing, Inc.
8. D.J. Thurman et al. Standards for epidemiologic studies and surveillance of epilepsy: ILAE epidemiology commission report. Epilepsia 2011; 52(Suppl. 7):2–26. Wiley Periodicals, Inc.
9. Ditto AM. Drug allergy. In: Grammer LC, Greenberger PA, editors. Patterson’s allergic diseases. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 295.
10. Jick H. Adverse drug reactions: the magnitude of the problem. J Allergy Clin Immunol 1984;74:555–7.
11. J Lazarou, B.H. Pomeranz, P.N. Corey. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200–5.
12. B.G. Katzung, A.J. Trevor. Basic and clinical pharmacology. 13th edition. New delhi: Mc Graw hill education (India) private limited; pg 18.
13. D.W. Bates, N. Spell, D.J. Cullen, E. Burdick, N. Laird , L.A. Petersen et al. The cost of adverse drug events in hospitalized patients. JAMA 1997; 277:307–11.
14. Shuen-lu Hung et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenetics and Genomics 2006; 16:297–306. Lippincott Williams & Wilkins.
15. The use of the WHO-UMC system for standardised case causality assessment. Available at:http://www.who.int/ medicines/areas/quality_safety/safety_efficacy/ WHOcausality_assessment.pdf
16. S.C. Hartwig, J. Siegel and P.J. Schneider. Preventability and Severity Assessment in Reporting Adverse Drug reactions. American Journal of Hospital Pharmacy. 1992;49:2229-31
17. R. Srinivasan, G. Ramya. Adverse drug reaction-causality assessment – Review article. International journal of research in pharmacy and chemistry. 2011; 1(3): 221-230.
Syed Arshaduddin A, Abid Ali M, Usha Sree T S, Margaret V, Shaima Z K. Analysis of adverse reactions with phenytoin and carbamazepine in tertiary care hospital – A retrospective study. Perspectives in Medical Research 2019; 7(1):75-78.